


Product Information

Construct:	Spike RBD (B.1.351 Variant) (SARS-CoV-2) (319-541-Avi-His)
Mutations:	K417N, E484K, N501Y
Concentration:	0.73 mg/ml
Species:	SARS-CoV-2
Formulated In:	8 mM phosphate pH 7.4, 110 mM NaCl, 2.2 mM KCl, 20% glycerol
Expression System:	HEK293
Format:	Aqueous buffer solution
Stability:	At least 6 months at -80°C. Avoid freeze/thaw cycles.
Storage:	-80°C
Genbank Accession:	MN908947
MW:	28 kDa
Glycosylation:	This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Purity:	≥90%
Assay Conditions:	Assay was done according to the Spike RBD (B.1.1.7 Variant) (N501Y) (SARS-CoV-2): ACE2 Inhibitor Screening Chemiluminescence Assay Kit (BPS Bioscience #78140) with various amounts of ACE2, His-Avi-Tag, Biotin-labeled HiP™ (BPS Bioscience #100665).
Application:	Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

Quality Control Data

4-20% SDS-Page Coomassie Staining



Spike RBD (B.1.351 Variant) (SARS-CoV-2) Activity

